Literature DB >> 18674549

The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents.

F Josef van der Staay1, Kris Rutten, Lars Bärfacker, Jean Devry, Christina Erb, Heike Heckroth, Dagmar Karthaus, Adrian Tersteegen, Marja van Kampen, Arjan Blokland, Jos Prickaerts, Klaus G Reymann, Ulrich H Schröder, Martin Hendrix.   

Abstract

The present study investigated the putative pro-cognitive effects of the novel selective PDE9 inhibitor BAY 73-6691. The effects on basal synaptic transmission and long-term potentiation (LTP) were investigated in rat hippocampal slices. Pro-cognitive effects were assessed in a series of learning and memory tasks using rodents as subjects. BAY 73-6691 had no effect on basal synaptic transmission in hippocampal slices prepared from young adult (7- to 8-week-old) Wistar rats. A dose of 10 microM, but not 30 microM, BAY 73-6691 enhanced early LTP after weak tetanic stimulation. The dose effective in young adult Wistar rats did not affect LTP in hippocampal slices prepared from young (7- to 8-week-old) Fischer 344 X Brown Norway (FBNF1) rats, probably reflecting strain differences. However, it increased basal synaptic transmission and enhanced early LTP after weak tetanic stimulation in hippocampal slices prepared from very old (31- to 35-month-old) FBNF1 rats. BAY 73-6691 enhanced acquisition, consolidation, and retention of long-term memory (LTM) in a social recognition task and tended to enhance LTM in an object recognition task. Bay 73-6691 attenuated the scoplamine-induced retention deficit in a passive avoidance task, and the MK-801-induced short-term memory deficits in a T-maze alternation task. The mechanism of action, possibly through modulation of the NO/cGMP-PKG/CREB pathway, is discussed. Our findings support the notion that PDE9 inhibition may be a novel target for treating memory deficits that are associated with aging and neurodegenerative disorders such as Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18674549     DOI: 10.1016/j.neuropharm.2008.07.005

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  46 in total

Review 1.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  Inhibition of phosphodiestrase 9 induces cGMP accumulation and apoptosis in human breast cancer cell lines, MCF-7 and MDA-MB-468.

Authors:  R Saravani; F Karami-Tehrani; M Hashemi; M Aghaei; R Edalat
Journal:  Cell Prolif       Date:  2012-04-02       Impact factor: 6.831

Review 3.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

4.  Structural Asymmetry of Phosphodiesterase-9A and a Unique Pocket for Selective Binding of a Potent Enantiomeric Inhibitor.

Authors:  Manna Huang; Yongxian Shao; Jianying Hou; Wenjun Cui; Beibei Liang; Yingchun Huang; Zhe Li; Yinuo Wu; Xinhai Zhu; Peiqing Liu; Yiqian Wan; Hengming Ke; Hai-Bin Luo
Journal:  Mol Pharmacol       Date:  2015-08-27       Impact factor: 4.436

5.  Age-related changes in nitric oxide activity, cyclic GMP, and TBARS levels in platelets and erythrocytes reflect the oxidative status in central nervous system.

Authors:  Elisa Mitiko Kawamoto; Andrea Rodrigues Vasconcelos; Sabrina Degaspari; Ana Elisa Böhmer; Cristoforo Scavone; Tania Marcourakis
Journal:  Age (Dordr)       Date:  2012-01-26

Review 6.  Alzheimer's disease and age-related memory decline (preclinical).

Authors:  Alvin V Terry; Patrick M Callahan; Brandon Hall; Scott J Webster
Journal:  Pharmacol Biochem Behav       Date:  2011-02-24       Impact factor: 3.533

Review 7.  Pharmacokinetics and pharmacodynamics of nitric oxide mimetic agents.

Authors:  Austin Horton; Isaac T Schiefer
Journal:  Nitric Oxide       Date:  2019-01-11       Impact factor: 4.427

8.  A novel PDE9 inhibitor WYQ-C36D ameliorates corticosterone-induced neurotoxicity and depression-like behaviors by cGMP-CREB-related signaling.

Authors:  Xian-Feng Huang; Wen-Tao Jiang; Li Liu; Fang-Chen Song; Xia Zhu; Gui-Lan Shi; Shu-Ming Ding; Heng-Ming Ke; Wei Wang; James M O'Donnell; Han-Ting Zhang; Hai-Bin Luo; Yi-Qian Wan; Guo-Qiang Song; Ying Xu
Journal:  CNS Neurosci Ther       Date:  2018-05-02       Impact factor: 5.243

9.  Cilostazol improves hippocampus-dependent long-term memory in mice.

Authors:  Shuichi Yanai; Yuki Semba; Hideki Ito; Shogo Endo
Journal:  Psychopharmacology (Berl)       Date:  2014-01-25       Impact factor: 4.530

Review 10.  Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.

Authors:  Olga A H Reneerkens; Kris Rutten; Harry W M Steinbusch; Arjan Blokland; Jos Prickaerts
Journal:  Psychopharmacology (Berl)       Date:  2008-08-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.